Research

Macro partitioning

GLP-1RAs and GIP/GLP-1RAs (liraglutide, semaglutide, tirzepatide) cause significant loss of fat-free (muscle) mass in older adults with sarcopenic obesity, posing a risk that may outweigh benefits if not managed.

If you are an older adult with sarcopenic obesity considering GLP-1 medications, expect to lose some muscle along with fat. To protect your strength, you must combine the medication with regular resistance exercise and eat enough protein (1.0-1.2g per kg of body weight). Work with your doctor to start slowly and monitor your function.

ModerateQualifiesMEDIUM confidence
These medications come with the risk of loss of muscle mass and an increased rate of adverse events. ... Trials to test subjective physical function included use of the physical functioning score ... Within a subgroup whose body composition was measured with DXA ... participants taking semaglutide lost 3.6% of their fat-free mass, vs. 0.1% in the placebo group ... participants treated with tirzepatide lost 10.9% of their fat-free mass compared with 2.6% in the placebo group.
Alissa S. Chen et al. · Diabetes · 2025

Why this rating

Evidence is derived from subgroup analyses of younger populations and secondary analyses; direct RCTs on sarcopenic obesity are lacking.

Source

Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges

Alissa S. Chen et al. · Diabetes · 2025

DOI 10.2337/dbi25-0004

narrative_reviewCited 15×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →